Dr. Bekaii-Saab Discusses PEGPH20 in Pancreatic Adenocarcinoma

Tanios Bekaii-Saab, MD
Published: Friday, Mar 02, 2018



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

In a phase Ib/II randomized study, the addition of PEGPH20 to mFOLFIRINOX in patients with metastatic pancreatic adenocarcinoma appeared to be detrimental, says Bekaii-Saab. This result was unexpected, and the survival with the addition of PEGPH20 was almost half that of mFOLFIRINOX alone.

Bekaii-Saab notes that although the results with PEGPH20 were disappointing, this trial showed that mFOLFIRINOX is beneficial alone. The estimated median overall survival (OS) in the mFOLFIRINOX arm was 15.1 months (95% CI, 10.1-15.7), while the estimated median OS with the addition of PEGPH20 was 7.6 months (95% CI, 4.6-9.2).


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

In a phase Ib/II randomized study, the addition of PEGPH20 to mFOLFIRINOX in patients with metastatic pancreatic adenocarcinoma appeared to be detrimental, says Bekaii-Saab. This result was unexpected, and the survival with the addition of PEGPH20 was almost half that of mFOLFIRINOX alone.

Bekaii-Saab notes that although the results with PEGPH20 were disappointing, this trial showed that mFOLFIRINOX is beneficial alone. The estimated median overall survival (OS) in the mFOLFIRINOX arm was 15.1 months (95% CI, 10.1-15.7), while the estimated median OS with the addition of PEGPH20 was 7.6 months (95% CI, 4.6-9.2).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Medical Crossfire®: Navigating Treatment Decisions in Pancreatic Cancer: Key QuestionsJun 29, 20191.5
Publication Bottom Border
Border Publication
x